LAPTM5 and lung carcinoma: There is a lot of data showing that LAPTM5 and PTPRC are not only co-expressed in AD/PD (Figure 5B), but also in systemic lupus erythematosus, lung cancer, and other diseases (Salih et al., 2019; Zhang et al., 2020, 2021).